"As Black as Ink": A Case of Alkaptonuria-Associated Myelopathy and a Review of the Literature.
Journal
Spine
ISSN: 1528-1159
Titre abrégé: Spine (Phila Pa 1976)
Pays: United States
ID NLM: 7610646
Informations de publication
Date de publication:
01 Jan 2019
01 Jan 2019
Historique:
pubmed:
23
6
2018
medline:
14
6
2019
entrez:
23
6
2018
Statut:
ppublish
Résumé
Case report and literature review. To characterize the rare presentation of myelopathy occurring secondary to alkaptonuria and to evaluate the available evidence regarding its treatment. Alkaptonuria is an autosomal recessive genetic condition with an estimated incidence of 1 in 250,000 to 1 in 1,000,000 people. Mutation of the enzyme homogentisate 1,2-dioxygenase leads to the production of high levels of homogentisic acid, with subsequent deposition in ligaments, cartilage, and menisci. Involvement of the spine is termed "ochronotic spondyloarthropathy," of which myelopathy is an uncommon presentation. We present the case of a 57-year-old man with alkaptonuria-associated myelopathy, who underwent surgical decompression. Ten additional cases were identified in the literature by a systematic search of PubMed and Google Scholar. In a patient presenting with myelopathy, alkaptonuria may be suspected because of medical history, family history, symptoms (including darkened urine, pigmented ear cartilage, and sclera), or radiographic changes, such as multilevel disc collapse, progressive wafer-like disc calcification, extensive osteophyte formation, and spinal deformity. The diagnosis can be confirmed by urine homogentisic acid testing. Of the 11 patients presented here or identified in the literature, 2 were treated nonoperatively, 8 were treated with decompressive spinal surgery, and treatment of the myelopathy was not discussed for 1 patient. In all cases in which outcomes were reported, substantial improvement in the patient's condition was seen. Alkaptonuria is a rare cause of myelopathy, but one that clinicians should understand. Although no disease-modifying treatment currently exists for alkaptonuria, the use of symptomatic treatments and, particularly, surgical decompression is recommended to address myelopathy if it develops. 4.
Sections du résumé
STUDY DESIGN
METHODS
Case report and literature review.
OBJECTIVE
OBJECTIVE
To characterize the rare presentation of myelopathy occurring secondary to alkaptonuria and to evaluate the available evidence regarding its treatment.
SUMMARY OF BACKGROUND DATA
BACKGROUND
Alkaptonuria is an autosomal recessive genetic condition with an estimated incidence of 1 in 250,000 to 1 in 1,000,000 people. Mutation of the enzyme homogentisate 1,2-dioxygenase leads to the production of high levels of homogentisic acid, with subsequent deposition in ligaments, cartilage, and menisci. Involvement of the spine is termed "ochronotic spondyloarthropathy," of which myelopathy is an uncommon presentation.
METHODS
METHODS
We present the case of a 57-year-old man with alkaptonuria-associated myelopathy, who underwent surgical decompression. Ten additional cases were identified in the literature by a systematic search of PubMed and Google Scholar.
RESULTS
RESULTS
In a patient presenting with myelopathy, alkaptonuria may be suspected because of medical history, family history, symptoms (including darkened urine, pigmented ear cartilage, and sclera), or radiographic changes, such as multilevel disc collapse, progressive wafer-like disc calcification, extensive osteophyte formation, and spinal deformity. The diagnosis can be confirmed by urine homogentisic acid testing. Of the 11 patients presented here or identified in the literature, 2 were treated nonoperatively, 8 were treated with decompressive spinal surgery, and treatment of the myelopathy was not discussed for 1 patient. In all cases in which outcomes were reported, substantial improvement in the patient's condition was seen.
CONCLUSION
CONCLUSIONS
Alkaptonuria is a rare cause of myelopathy, but one that clinicians should understand. Although no disease-modifying treatment currently exists for alkaptonuria, the use of symptomatic treatments and, particularly, surgical decompression is recommended to address myelopathy if it develops.
LEVEL OF EVIDENCE
METHODS
4.
Identifiants
pubmed: 29933333
doi: 10.1097/BRS.0000000000002755
pii: 00007632-201901010-00019
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
E53-E59Références
Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med 2002; 347:2111–2121.
Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D, et al. The molecular basis of alkaptonuria. Nat Genet 1996; 14:19–24.
Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902. Mol Med 1996; 2:274–282.
Mannoni A, Selvi E, Lorenzini S, et al. Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin Arthritis Rheum 2004; 33:239–248.
Hamdi N, Cooke TD, Hassan B. Ochronotic arthropathy: case report and review of the literature. Int Orthop 1999; 23:122–125.
Rana AQ, Saeed U, Abdullah I. Alkaptonuria, more than just a mere disease. J Neurosci Rural Pract 2015; 6:257–260.
Akeda K, Kasai Y, Kawakita E, et al. Thoracic myelopathy with alkaptonuria. Spine (Phila Pa 1976) 2008; 33:E62–E65.
Onda A, Kikuchi S, Yabuki S, et al. A case of thoracic myelopathy secondary to alkaptonuric spondylosis. J Orthop Sci 2012; 17:495–499.
Bozkurt S, Aktekin L, Ugurlu FG, et al. An unusual cause of myelopathy: ochronotic spondyloarthropathy with positive HLA B27. Am J Phys Med Rehabil 2017; 96:e206–e209.
Li N, Tian W, Yuan Q, et al. Cervical spondylotic myelopathy due to the ochronotic arthropathy of the cervical spine. J Korean Neurosurg Soc 2016; 59:65–68.
Reddy R, Vijayasaradhi M, Biswal D. Focal ligamentum flavum hypertrophy with ochronotic deposits: an unusual cause for neurogenic claudication in alkaptonuria. Asian Spine J 2012; 6:148–151.
Kusakabe N, Tsuzuki N, Sonada M. Compression of the cervical cord due to alcaptonuric arthropathy of the atlanto-axial joint. A case report. J Bone Joint Surg Am 1995; 77:274–277.
Mavra M, Chadha G, Henein MM, et al. Alcaptonuria with myelopathy and neuropathy. Med Principles Pract 1999; 8:73–76.
Wilke A, Steverding D. Ochronosis as an unusual cause of valvular defect: a case report. J Med Case Rep 2009; 3:9302.
Rahimizadeh A, Soufiani H, Hassani V, et al. Symptomatic pseudarthrosis in ochronotic spine: case report. J Neurosurg Spine 2017; 26:220–228.
Sharma RR, Ravi R, Bhama BA, et al. Cervico-medullary compression secondary to ochronotic arthritis affecting cranio-vertebral joints syndesmo-dental ochronotic arthritis. J Postgrad Med 1988; 34:253–257.
Srinivasan V, Natarajan N, Subramanian G. A case of alkaptonuric ochronosis producing spinal cord compression. J Assoc Physicians India 1971; 19:49–51.
Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol 2013; 66:367–373.
Laskar FH, Sargison KD. Ochronotic arthropathy. A review with four case reports. J Bone Joint Surg Br 1970; 52:653–666.
Introne WJ, Gahl WA. Adam MP, Ardinger HH, Pagon RA, et al. Alkaptonuria. University of Washington, GeneReviews. Seattle, WA: 2003.
Wolff JA, Barshop B, Nyhan WL, et al. Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res 1989; 26:140–144.
De Haas V, Carbasius Weber EC, De Klerk JB, et al. The success of dietary protein restriction in alkaptonuria patients is age-dependent. J Inherit Metab Dis 1998; 21:791–798.